It has not been evaluated or approved by the U.S
PMID 3927946

(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)

Erythropoiesis: a brief overview of its steps and regulation Erythron comprising circulating erythrocytes and their precursor cells in the bone marrow provides a critical function of oxygen transport [22]
Recalls & Warnings August 30, 2012 FDA Warns of Medical Claims Made For Numerous Chinese Herbal Products On August 15, 2012, the FDA warned Dragon Herbs that promotional statements made on the company's website constitute drug claims for twenty herbal products, including CardioPro 2000, Cordyceps, Duanwood Reishi, Gynostemma, Ginseng and Astragalus Combination, Dang Gui and Gelatin, Sweet Relief,
Read on to find out how, and be sure to leave a comment, share to let us know what you think